The clinical course of EAE is reflected by the dynamics of the neuroantigen-specific T cell compartment in the blood

Clinical Immunology

Volumn 137, Issue 3, 2010, Pages 422-432

  Kuerten, Stefanie ^a   Rottlaender, Andrea ^a   Rodi, Michael ^a   Velasco, Virgilio B ^b   Schroeter, Michael ^a,b   Kaiser, Claudia ^a   Addicks, Klaus ^a   Tary Lehmann, Magdalena ^c   Lehmann, Paul V ^b,c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Cellular Technology Limited   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cytokines; EAE; ELISPOT; Immune monitoring; MS

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; INTERFERON PRODUCTION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GLYCOPROTEINS; INTERFERON-GAMMA; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MYELIN PROTEOLIPID PROTEIN; NEURONS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; T-LYMPHOCYTES;

EID: 78149283317     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.09.004     Document Type: Article

References (46)

1. Goverman J., Brabb T. Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis. Lab. Anim. Sci. 1996, 46:482-492.
2. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
3. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
4. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
5. Tuohy V.K., Lu Z., Sobel R.A., Laursen R.A., Lees M.B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 1989, 142:1523-1527.
6. Sobel R.A., Tuohy V.K., Lu Z.J., Laursen R.A., Lees M.B. Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein. J. Neuropathol. Exp. Neurol. 1990, 49:468-479.
7. Mendel I., de Rosbo N.K., Ben Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur. J. Immunol. 1995, 25:1951-1959.
8. Mendel I., de Rosbo N.K., Ben Nun A. Delineation of the minimal encephalitogenic epitope within the immunodominant region of myelin oligodendrocyte glycoprotein: diverse V beta usage by T cells recognizing the core epitope encephalitogenic for T cell receptor V beta b and T cell receptor V beta in H-2b mice. Eur. J. Immunol. 1996, 26:2470-2479.
9. Potter N.T., Stephens T.S. Humoral immune recognition of proteolipid protein (PLP)-specific epitopes in the SJL/J mouse. J. Neurosci. Res. 1994, 37:15-22.
10. McRae B.L., Miller S.D. Fine specificity of CD4+ T cell responses to the dominant encephalitogenic PLP 139-151 peptide in SJL/J mice. Neurochem. Res. 1994, 19:997-1004.
11. Hjelmstrom P., Juedes A.E., Fjell J., Ruddle N.H. B-cell deficient mice develop experimental autoimmune encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J. Immunol. 1998, 161:4480-4483.
12. Oliver A.R., Lyon G.M., Ruddle N.H. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J. Immunol. 2003, 171:462-468.
13. Merrill J.E., Kono D.H., Clayton J., Ando D.G., Hinton D.R., Hofman F.M. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc. Natl Acad. Sci. USA 1992, 89:574-578.
14. Navikas V., Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Res. 1996, 45:322-333.
15. Hofstetter H.H., Karulin A.Y., Forsthuber T.G., Ott P.A., Tary-Lehmann M., Lehmann P.V. The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice. J. Neuroimmunol. 2005, 170:105-114.
16. Hofstetter H.H., Forsthuber T.G. Kinetics of IL-17- and interferon-gamma producing PLPp-specific CD4 T cells in EAE induced by coinjection of PLP/IFA with pertussis toxin in SJL mice. Neurosci. Lett. 2010, 476:150-155.
17. Hofstetter H.H., Ibrahim S.M., Koczan D., Kruse N., Weishaupt A., Toyka K.V., Gold R. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell. Immunol. 2005, 237:123-130.
18. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
19. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:566-573.
20. Hofstetter H.H., Targoni O.S., Karulin A.Y., Forsthuber T.G., Tary-Lehmann M., Lehmann P.V. Does the frequency and the avidity spectrum of the neuroantigen-specific T cells in the blood mirror the autoimmune process in the central nervous system of mice undergoing experimental allergic encephalomyelitis?. J. Immunol. 2005, 174:4598-4605.
21. Kuerten S., Kostova-Bales D.A., Frenzel L.P., Tigno J.T., Tary-Lehmann M., Angelov D.N., Lehmann P.V. MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum. J. Neuroimmunol. 2007, 189:31-40.
22. Mahad D.J., Lawry J., Howell S.J.L., Woodroofe M.N. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse. Mult. Scler. 2003, 9:189-198.
23. Bielekova B., Martin R. Development of biomarkers in multiple sclerosis. Brain 2004, 127:1463-1478.
24. Rinaldi L., Gallo P. Immunological markers in multiple sclerosis: tackling the missing elements. Neurol. Sci. 2005, 26:S215-S217.
25. Reindl M., Khalil M., Berger T. Antibodies as biological markers for pathophysiological processes in multiple sclerosis. J. Neuroimmunol. 2006, 180:50-62.
26. Lutterotti A., Berger T., Reindl M. Biological markers for multiple sclerosis. Curr. Med. Chem. 2007, 14:1956-1965.
27. Fox R.J., Kivisakk P., Fisher E., Tucky B., Lee J.C., Rudick R.A., Ransohoff R.M. Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury. Mult. Scler. 2008, 14:1036-1043.
28. H17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-Bet mRNA predict the response to interferon-beta treatment?. J. Neuroimmunol. 2009, 215:90-95.
29. Sawai S., Umemura H., Mori M., Satoh M., Hayakawa S., Kodera Y., Tomonaga T., Kuwabara S., Nomura F. Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: proteomic analysis. J. Neuroimmunol. 2010, 218:112-115.
30. Pelfrey C.M., Rudick R.A., Cotleur A.C., Lee J.C., Tary-Lehmann M., Lehmann P.V. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J. Immunol. 2000, 165:1641-1651.
31. Hohlfeld R., Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl Acad. Sci. USA 2004, 101:14599-14606.
32. Lehmann P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992, 358:155-157.
33. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 1995, 182:75-85.
34. Vanderlugt C.L., Begolka W.S., Neville K.L., Katz-Lewy Y., Howard L.M., Eagar T.N., Bluestone J.A., Miller S.D. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol. Rev. 1998, 164:63-72.
35. Vanderlugt C.L., Neville K.L., Nikcevich K.M., Eagar T.N., Bluestone J.A., Miller S.D. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing remitting experimental autoimmune encephalomyelitis. J. Immunol. 2000, 164:670-678.
36. Tuohy V.K., Yu M., Yin L., Kawczak J.A., Johnson J.M., Mathisen P.M., Weinstock-Guttman B., Kinkel R.P. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 1998, 164:93-100.
37. Begolka W.S., Vanderlugt C.L., Rahbe S.M., Miller S.D. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol. 1998, 161:4437-4446.
38. Pribyl T.M., Campagnoni C.W., Kampf K., Kashima T., Handley V.W., McMahon J., Campagnoni A.T. The human myelin basic protein gene is included within a 179-kilobase transcription unit: expression in the immune and central nervous systems. Proc. Natl Acad. Sci. USA 1993, 90:10695-10699.
39. Pribyl T.M., Campagnoni C., Kampf K., Handley V.W., Campagnoni A.T. The major myelin protein genes are expressed in the human thymus. J. Neurosci. Res. 1996, 45:812-819.
40. Fritz R.B., Kalvakolanu I. Thymic expression of the golli-myelin basic protein gene in the SJL/J mouse. J. Neuroimmunol. 1995, 57:93-99.
41. Kawakami N., Lassmann S., Li Z., Odoardi F., Ritter T., Ziemssen T., Klinkert W.E., Ellwart J.W., Bradl M., Krivacic K., Lassmann H., Ransohoff R.M., Volk H.D., Wekerle H., Linington C., Flügel A. The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J. Exp. Med. 2004, 1999:185-197.
42. Astier A.L., Meiffren G., Freeman S., Hafler D.A. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 2006, 116:3252-3257.
43. Zozulya A.L., Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat. Clin. Pract. Neurol. 2008, 4:384-398.
44. Ma A., Xiong Z., Hu Y., Qi S., Song L., Dun H., Zhang L., Lou D., Yang P., Zhao Z., Wang X., Zhang D., Daloze P., Chen H. Dysfunction of IL-10-producing type 1 regulatory T cells and CD4(+)CD25(+) regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkey. Int. Immunopharmacol. 2009, 9:599-608.
45. Stromnes I.M., Goverman J.M. Passive induction of experimental allergic encephalomyelitis. Nat. Prot. 2006, 1:1952-1960.
46. Shi G., Cox C.A., Vistica B.P., Wawrousek E.F., Gery I. Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. J. Immunol. 2008, 181:7205-7213.